<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wei MX</submitter><funding>Natural Science Foundation of Ningxia Province</funding><funding>National Natural Science Foundation of China</funding><funding>Ningxia University</funding><pagination>18333-18341</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9033422</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(30)</volume><pubmed_abstract>For the first time, six novel artemisone-piperazine-tetronamide hybrids (12a-f) were efficiently synthesised from dihydroartemisinin (DHA) and investigated for their &lt;i>in vitro&lt;/i> cytotoxicity against some human cancer cells and benign cells. All the targets showed good cytotoxic activity &lt;i>in vitro&lt;/i>. Hybrid 12a exhibited much better inhibitory activity against human liver cancer cell line SMMC-7721 (IC&lt;sub>50&lt;/sub> = 0.03 ± 0.04 μM for 24 h) than the parent DHA (IC&lt;sub>50&lt;/sub> > 0.7 μM), and two references, vincristine (VCR; IC&lt;sub>50&lt;/sub> = 0.27 ± 0.03 μM) &amp; cytosine arabinoside (ARA; IC&lt;sub>50&lt;/sub> = 0.63 ± 0.04 μM). Furthermore, hybrid 12a had low toxicity against human benign liver cell line LO2 (IC&lt;sub>50&lt;/sub> = 0.70 ± 0.02 μM for 24 h) compared with VCR, ARA, and DHA &lt;i>in vitro&lt;/i>. Moreover, the inhibitory activity of hybrid 12a was obviously enhanced when human liver cancer cell line MHCC97H absorbed Fe&lt;sup>2+&lt;/sup> &lt;i>in vitro&lt;/i>.</pubmed_abstract><journal>RSC advances</journal><pubmed_title>Synthesis and biological evaluation of novel artemisone-piperazine-tetronamide hybrids.</pubmed_title><pmcid>PMC9033422</pmcid><funding_grant_id>21462032</funding_grant_id><funding_grant_id>2021AAC05009</funding_grant_id><funding_grant_id>2019AAC03018</funding_grant_id><funding_grant_id>G2020107490003</funding_grant_id><pubmed_authors>Zhang SS</pubmed_authors><pubmed_authors>Li XQ</pubmed_authors><pubmed_authors>Yang JH</pubmed_authors><pubmed_authors>He Y</pubmed_authors><pubmed_authors>Wei MX</pubmed_authors><pubmed_authors>Liu XX</pubmed_authors><pubmed_authors>Yu JY</pubmed_authors><pubmed_authors>Yang PW</pubmed_authors><pubmed_authors>Zhang MW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis and biological evaluation of novel artemisone-piperazine-tetronamide hybrids.</name><description>For the first time, six novel artemisone-piperazine-tetronamide hybrids (12a-f) were efficiently synthesised from dihydroartemisinin (DHA) and investigated for their &lt;i>in vitro&lt;/i> cytotoxicity against some human cancer cells and benign cells. All the targets showed good cytotoxic activity &lt;i>in vitro&lt;/i>. Hybrid 12a exhibited much better inhibitory activity against human liver cancer cell line SMMC-7721 (IC&lt;sub>50&lt;/sub> = 0.03 ± 0.04 μM for 24 h) than the parent DHA (IC&lt;sub>50&lt;/sub> > 0.7 μM), and two references, vincristine (VCR; IC&lt;sub>50&lt;/sub> = 0.27 ± 0.03 μM) &amp; cytosine arabinoside (ARA; IC&lt;sub>50&lt;/sub> = 0.63 ± 0.04 μM). Furthermore, hybrid 12a had low toxicity against human benign liver cell line LO2 (IC&lt;sub>50&lt;/sub> = 0.70 ± 0.02 μM for 24 h) compared with VCR, ARA, and DHA &lt;i>in vitro&lt;/i>. Moreover, the inhibitory activity of hybrid 12a was obviously enhanced when human liver cancer cell line MHCC97H absorbed Fe&lt;sup>2+&lt;/sup> &lt;i>in vitro&lt;/i>.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 May</publication><modification>2025-04-05T20:04:24.245Z</modification><creation>2025-04-05T20:04:24.245Z</creation></dates><accession>S-EPMC9033422</accession><cross_references><pubmed>35480921</pubmed><doi>10.1039/d1ra00750e</doi></cross_references></HashMap>